Atea Pharmaceuticals (AVIR) Capital Expenditures: 2018-2022
Historic Capital Expenditures for Atea Pharmaceuticals (AVIR) over the last 5 years, with Dec 2022 value amounting to $1.9 million.
- Atea Pharmaceuticals' Capital Expenditures was N/A to $20,000 in Q3 2022 from the same period last year, while for Sep 2022 it was $1.9 million, marking a year-over-year change of. This contributed to the annual value of $1.9 million for FY2022, which is 48475.00% up from last year.
- According to the latest figures from FY2022, Atea Pharmaceuticals' Capital Expenditures is $1.9 million, which was up 48,475.00% from $4,000 recorded in FY2021.
- Atea Pharmaceuticals' 5-year Capital Expenditures high stood at $1.9 million for FY2022, and its period low was $2,000 during FY2019.
- For the 3-year period, Atea Pharmaceuticals' Capital Expenditures averaged around $657,667, with its median value being $26,000 (2020).
- Its Capital Expenditures has fluctuated over the past 5 years, first plummeted by 84.62% in 2021, then spiked by 48,475.00% in 2022.
- Atea Pharmaceuticals' Capital Expenditures (Yearly) stood at $12,000 in 2018, then slumped by 83.33% to $2,000 in 2019, then surged by 1,200.00% to $26,000 in 2020, then tumbled by 84.62% to $4,000 in 2021, then surged by 48,475.00% to $1.9 million in 2022.